Table 1.
The Correlation between VETC and Clinical Parameters and Imagine Features.
| Parameters | VETC | χ2 | P-Value | |
|---|---|---|---|---|
| Negative | Positive | |||
| Age | 51.21 ± 10.80 | 48.60 ± 12.31 | .058 | |
| Gender | ||||
| Female | 38 (82.61%) | 8 (17.39%) | 1.2040 | .2725 a |
| Male | 240 (75.24%) | 79 (24.76%) | ||
| LMR | ||||
| ≤7.75 | 267 (77.39%) | 78 (22.61%) | 5.2208 | .0223 a |
| >7.75 | 11 (55.00%) | 9 (45.00%) | ||
| PLR | ||||
| ≤40 | 108 (82.44%) | 23 (17.56%) | 4.4367 | .0352 a |
| >40 | 170 (72.65%) | 64 (27.35%) | ||
| Neutrophil | ||||
| ≤7 | 267 (77.39%) | 78 (22.61%) | 5.2208 | .0352 a |
| >7 | 11 (55.00%) | 9 (45.00%) | ||
| GPR | ||||
| ≤.17 | 67 (83.75%) | 13 (16.25%) | 3.2474 | .0715 a |
| >.17 | 211 (74.04%) | 74 (25.96%) | ||
| AAR | ||||
| ≤.86 | 128 (82.05%) | 28 (17.95%) | 5.2007 | .0226 a |
| >.86 | 150 (71.77%) | 59 (28.23%) | ||
| ALRI | ||||
| ≤29.75 | 213 (80.08%) | 53 (19.92%) | 8.2622 | .0040 a |
| >29.75 | 65 (65.66%) | 34 (34.34%) | ||
| ANRI | ||||
| ≤12.43 | 187 (79.91%) | 47 (20.09%) | 5.0507 | .0246 a |
| >12.43 | 91 (69.47%) | 40 (30.53%) | ||
| APRI | ||||
| ≤.21 | 149 (80.98%) | 35 (19.02%) | 4.7364 | .0295 a |
| >.21 | 129 (71.27%) | 52 (28.73%) | ||
| BLRI | ||||
| ≤21.73 | 149 (81.42%) | 34 (18.58%) | 5.5856 | .0181 a |
| >21.73 | 129 (70.88%) | 53 (29.12%) | ||
| SII | ||||
| ≤545.6 | 212 (78.81%) | 57 (21.19%) | 3.9444 | .0470 a |
| >545.6 | 66 (68.75%) | 30 (31.25%) | ||
| SIRI | ||||
| ≤.64 | 79 (71.82%) | 31 (28.18%) | 1.6383 | .2006 a |
| >.64 | 199 (78.04%) | 56 (21.96%) | ||
| ALT | ||||
| ≤40 | 145 (77.96%) | 41 (22.04%) | .6713 | .4126 a |
| >40 | 133 (74.30%) | 46 (25.70%) | ||
| AST | ||||
| ≤45 | 201 (78.82%) | 54 (21.18%) | 3.2957 | .0695 a |
| >45 | 77 (70.00%) | 33 (30.00%) | ||
| TB | ||||
| ≤17.1 | 221 (76.21%) | 69 (23.79%) | .0014 | .9701 a |
| >17.1 | 57 (76.00%) | 18 (24.00%) | ||
| PT | ||||
| ≤13.5 | 269 (76.64%) | 82 (23.36%) | 1.1315 | .2874 a |
| >13.5 | 9 (64.29%) | 5 (35.71%) | ||
| HBV infection | ||||
| Negative | 37 (86.05%) | 6 (13.95%) | 2.6220 | .1054 a |
| Positive | 241 (74.84%) | 81 (25.16%) | ||
| Splenomegaly | ||||
| Negative | 231 (76.24%) | 72 (23.76%) | .0053 | .9421 a |
| Positive | 47 (75.81%) | 15 (24.19%) | ||
| Liver cirrhosis | ||||
| Negative | 215 (75.17%) | 71 (24.83%) | .7127 | .3985 a |
| Positive | 63 (79.75%) | 16 (20.25%) | ||
| Tumor number | ||||
| Solitary | 243 (76.66%) | 74 (23.34%) | .3211 | .5709 a |
| Multiple | 35 (72.92%) | 13 (27.08%) | ||
| Ascites | ||||
| Negative | 274 (75.90%) | 87 (24.10%) | .0000 | .5764 b |
| Positive | 4 (100.00%) | 0 (.00%) | ||
| Tumor envelope | ||||
| Complete | 179 (74.27%) | 62 (25.73%) | 1.3966 | .2373 a |
| Incomplete | 99 (79.84%) | 25 (20.16%) | ||
| TNM_stage | ||||
| I-II | 260 (94%) | 77 (89%) | 1.702 | .1921 a |
| III-IV | 18 (6%) | 10 (11%) | ||
| Tumor diameter (ln) | 1.46 (1.06,1.80) | 1.78 (1.41,2.19) | <.0001 | |
| AFP(ln) | 4.77±3.32 | 4.5415±3.15 | <.0001 | |
aPearson chi-square test.
bFisher’s exact test.
VETC: Vessels that encapsulate tumor cluster; LMR: lymphocyte to monocyte ratio; PLR: platelet-lymphocyte ratio; GPR: γ-glutamyl transpeptidase to platelet ratio; AAR: AST to ALT ratio; ALRI: AST to lymphocyte ratio index; ANRI: AST to neutrophil ratio index; APRI: AST to platelet ratio index; BLRI: ALT to lymphocyte ratio index; SII: systemic immune-inflammation index; SIRI: systemic inflammation response index.